Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, President, Clinical Services and Chief Medical Officer, Nashville, Tennessee-based HCA (Hospital Corporation of America). “The Honorable Jonathan B. Perlin” was Under Secretary for Health in the U.S. Department of Veterans Affairs, led the nation’s largest integrated health system. Nominated for: Developed the Sepsis Protection and Optimization of Therapy (SPOT) program to serve as an early warning system for sepsis.
Sarkis Mazmanian, PhD, and Immunology, PhD., Beta Kappa UCLA, Luis & Nelly Soux Professor of Microbiology, CalTech. was named by Discover Magazine as one of the “Best Brains in Science under 40”, “Life Science Superstar” by Genetic Engineering and Biotechnology News, and recently received the MacArthur Foundation “Genius” award. Nominated for: Discovery and Deployment of a Novel Probiotic Treatment for Autism by demonstrating the cause and effect relationship between microbes in the gut and the symptoms associated with Autism Spectrum Disorder (ASD), which affects three million Americans with a cost of $250 billion annually. His laboratory focuses on research into the human gut microbiome to understand the causes of various immunologic and neurologic disorders, with a specific focus on developing probiotic therapies for Crohn’s disease, autism spectrum disorder, and Parkinson’s disease.
Dr. Mark J. Manary, MD Helene B. Roberson Professor of Pediatrics, School of Medicine, Washington University in St. Louis. Nominated for: Ready-to-Use-Therapeutic Food (RUTF) Since 1994, Dr. Manary has made it his life’s work to eradicate childhood malnutrition in Africa and has since become known as one of the world’s foremost experts in childhood malnutrition. Dr. Manary was at the forefront of the advent of ready-to-use-therapeutic food (RUTF), an energy-dense, peanut butter paste with proven efficacy treating children with severe acute malnutrition (SAM) His work also includes the development and introduction of new food crops and integrating nutrition care in HIV treatment programs.
Heinz-Josef Lenz, M.D., FACP, Professor of Medicine and Preventive Medicine, holds J Terrence Lanni Chair for Cancer Research and is the Associate Director for Clinical Sciences at the USC Norris Comprehensive Cancer Center at the USC Keck School of Medicine. Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California. https://keck.usc.edu/faculty-search/heinz-josef-lenz/ Nominated for: Impact of Consensus Molecular Subtype (CMS) on Survival in Patients With Metastatic Colorectal Cancer. An active researcher, Dr. Lenz focuses on identification of predictive and prognostic biomarker and is an expert on early drug development. His findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment for the management of metastatic disease, which would lead to improve the patient’s quality of life.
Robert A. Kloner, MD, PhD, is Chief Science Officer and Director of Cardiovascular Research at Huntington Medical Research Institutes (HMRI). He serves as Professor of Medicine (Clinical Scholar) at Keck School of Medicine at University of Southern California (USC) and is an attending cardiologist at Los Angeles County/ USC Medical Center. Nominated for: Recognition and research of the No-reflow phenomenon; a deadly consequence of heart attacks and his research into the long-term effects of e-cigarettes on the cardiovascular system and heart attacks.
Nominated for: Leading the Cellular Immunotherapy Center at City of Hope; groundbreaking work in developing CAR T cell therapies for lymphoma, leukemia, myeloma, breast concert with brain metastasis, prostate cancer and glioblastoma, using the body’s own immune system to target cancer.